Table 1.
Baseline characteristics of study participants by study.
| Characteristic | UKB n = 308182 |
WHS n = 26 204 |
FHS n = 2839 |
|---|---|---|---|
| Age, median (25th–75th; years) | 56.00 (49.00; 62.00) | 52.7 (48.9; 58.7) | 52.0 (46.0; 59.0) |
| Female sex, n (%) | 178917 (58.1) | 26 204 (100) | 1498 (52.8) |
| Non-white race, n (%) | 49675 (16.1) | 1435 (5.5) | 0 (0) |
| BMI, median (25th–75th; kg/m 2 ) | 26.3 (23.8; 29.3) | 24.8 (22.3; 28.3) | 26.13 (23.5; 29.1) |
| Systolic blood pressure, median (25th–75th; mmHg) | 135.0 (123.5; 148.0) | 125.0 (115.0; 135.0) | 126.0 (115.0; 138.0) |
| Use of blood pressure-lowering medication, n (%) | 40 367 (13.1) | 3191 (12.2) | 447 (15.7) |
| Use of LDL-C-lowering medication, n (%) | 0 (0) | 0 (0) | 0 (0) |
| Smoking, n (%) | 179986 (58.4)a | 12623 (48.2)a | 659 (23.2)b |
| Diabetes, n (%) | 4570 (1.5) | 597 (2.3) | 134 (4.7) |
| Total cholesterol, median (25th–75th; mg/dl) | 225.2 (199.4; 252.8) | 207.0 (183.0; 235.0) | 205.0 (181.0; 229.0) |
| HDL-C, median (25th–75th; mg/dl) | 55.8 (47.0; 66.4) | 52.0 (43.3; 62.4) | 48.0 (40.0; 59.0) |
| Triglycerides, median (25th–75th; mg/dl) | 125.2 (89.2; 178.7) | 116.0 (82.0; 168.0) | 98.0 (68.0; 146.0) |
| Non-HDL-C, median (25th–75th; mg/dl) | 167.4 (142.5; 194.2) | 152.5 (128.0; 179.4) | 154.0 (128.0; 181.0) |
| LDL-C, median, (25th–75th; mg/dl) | 141.5 (121.6; 163.0) | 120.9 (100.3; 143.6) | 131.0 (108.0; 155.0) |
| ApoB, median (25th–75th; mg/dl) | 104.7 (90.0; 120.2) | 99.0 (83.2; 119.6) | 98.0 (83.0; 114.0) |
| LDL-C/ApoB, median (25th–75th; mg/dl) | 1.35 (1.30; 1.41) | 1.21 (1.10; 1.33) | 1.35 (1.22; 1.46) |
| ASCVDc 10-year risk, median (25th–75th; %) | 4.56 (1.91; 9.55) | 2.05 (1.12; 4.28) | 4.0 (1.5, 9.2) |
Median and interquartile ranges for continuous variables and numbers and percentages for categorical data.
a
Current or former.
b
Current smoker.
c
Atherosclerotic cardiovascular disease.